“What I found exciting was that the extent to which a…PI-RADS 4 score saved biopsies without really affecting the likelihood of detecting clinically significant tumor,” says Stella K. Kang, MD.
In this video, Stella K. Kang, MD, discusses notable findings from the recent Radiology study, “Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness,” for which she served as a study author. Kang is an associate professor of radiology and population health and director of Comparative Effectiveness and Outcomes Research in the department of radiology at NYU Grossman School of Medicine, New York.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.